Brought to you by 
Alere buys eScreen for $270mm in cash, up to $70mm in earn-outs
21 May 2012
Executive Summary
Point-of-care diagnostics company Alere Inc. has acquired private drugs-of-abuse screening firm eScreen Inc. for $270mm in cash up front, plus another $70mm in earn-outs.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
- Services
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Urine-based Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alere buys eScreen for $270mm in cash, up to $70mm in earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice